Arena and Vivus Take Divergent Paths To CRL Response
This article was originally published in The Pink Sheet Daily
Executive Summary
Lorqess and Qnexa both have received "complete responses" from FDA, but the drastically different contents of the letters have shaped divergent responses from the drugs' sponsors.
You may also be interested in...
Positive Panel Recommendation For Contrave Could Change Obesity Drug Game
FDA's Endocrinologic and Metabolic Drugs Advisory Committee's surprise vote recommending Orexigen Therapeutics’ obesity drug Contrave (naltrexone SR/bupropion SR) for approval has boosted hopes that at least some of the current generation of obesity drugs in development may reach the market – just not in the order that everyone had expected.
Positive Panel Recommendation For Contrave Could Change Obesity Drug Game
FDA's Endocrinologic and Metabolic Drugs Advisory Committee's surprise vote recommending Orexigen Therapeutics’ obesity drug Contrave (naltrexone SR/bupropion SR) for approval has boosted hopes that at least some of the current generation of obesity drugs in development may reach the market – just not in the order that everyone had expected.
FDA, Orexigen Discussing CV Risk Study For Weight-Loss Drug Contrave
Timing of the study to be discussed at Dec. 7 advisory committee meeting.